Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell Corporation (Nasdaq: ICCC) announced the closure of an equity investment on April 14, 2021, raising $4,250,037 by issuing 515,156 common shares at $8.25 each to its largest stockholder and other investors. The funds will facilitate growth initiatives, including increasing production capacity for First Defense® from $23 million to $30 million per year, conducting marketing studies, and expanding vaccine production. A conference call is scheduled for May 14, 2021, to discuss the investment and financial results.
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary unaudited sales results for Q1 2021, revealing a 16% decline in total product sales, equating to a decrease of $791,000 compared to Q1 2020, totaling approximately $4.1 million. The decrease was anticipated due to higher beginning inventory last year. Despite this, the company noted a backlog of orders of approximately $3 million, indicating strong demand. Plans to increase annual production capacity from $16.5 million to $23 million are on schedule, expected to be completed by June 30, 2021.
ImmuCell Corporation (Nasdaq: ICCC) reported an increase in total product sales by $1.6 million, or 12%, to $15.3 million for the year ended December 31, 2020. The company submitted a crucial FDA filing for Re-Tain™, a mastitis product, with a response expected in Q3 2021. A backlog of orders worth $1.8 million was noted, attributed to COVID-19 disruptions. Gross margin decreased to 45% in 2020, attributed to higher fixed costs. Net loss improved to $1.022 million ($0.14 per share) compared to $1.296 million ($0.19 per share) in 2019. EBITDA increased to $1.893 million.
ImmuCell Corporation (Nasdaq: ICCC) will report unaudited financial results for the year ending December 31, 2020, on February 22, 2021. A conference call is scheduled for February 23, 2021, at 9:00 AM ET, to discuss the results. Interested parties can join by calling (844) 855-9502 (toll-free) or (412) 317-5499 (international). Following the call, a replay will be available for seven days. The company’s updated Corporate Presentation will be accessible on its website after the market closes on February 22, 2021, with the Annual Report on Form 10-K expected by March 30, 2021.
ImmuCell Corporation (Nasdaq: ICCC) announced a 12% increase in preliminary, unaudited product sales, reaching approximately $15.3 million for 2020. Strong demand for the First Defense® product line has led to a production backlog estimated at $1.8 million. To meet this demand, the company plans a $3.5 million investment to expand production capacity to about $23 million annually, up from $16.5 million. Additionally, the launch of the Re-Tain™ product is anticipated in Q3 2021, depending on FDA approval timelines.
ImmuCell Corporation (Nasdaq: ICCC) has announced a restructuring of its bank debt, securing a $1.5 million loan from Gorham Savings Bank. This loan features a seven-year term with an interest rate of 3.5% per annum. Approximately $624,000 of the loan will pay down an outstanding mortgage balance, while around $876,000 will be allocated for closing costs and working capital. The CEO, Michael F. Brigham, highlighted that this financial backing will enhance the company's liquidity and support its expansion plans.
ImmuCell Corporation (Nasdaq: ICCC) reported a 25% increase in product sales, reaching $3.7 million for Q3 2020, compared to the same period in 2019. Year-to-date sales rose 15% to $11.6 million. The backlog of orders decreased from $945,000 to $130,000, indicating improved production efficiency. Net loss narrowed to $323,000 ($0.04/share) from $503,000 ($0.07/share) year-on-year. Gross margins declined slightly, and product development expenses rose to $1.1 million. The company anticipates further growth in 2021.
ImmuCell Corporation (Nasdaq: ICCC) will announce its unaudited financial results for Q3 2020 on November 12, 2020, after market close. A conference call to discuss these results is scheduled for November 13, 2020, at 9:00 AM ET. Investors can join the call via designated phone numbers. The company encourages reviewing its upcoming Quarterly Report on Form 10-Q post-announcement and its updated Corporate Presentation available on its website. ImmuCell specializes in developing practical products to enhance the health of dairy and beef calves.
ImmuCell Corporation (Nasdaq: ICCC) announced its preliminary, unaudited sales results for Q3 2020, revealing a 25% increase in product sales to $3.7 million compared to Q3 2019. For the nine-month period, sales rose 15% to $11.6 million. The company has significantly reduced its order backlog to $130,000 as of September 30, 2020. Management highlights continued growth driven by the Tri-Shield First Defense® product, which provides immediate immunity for calves. Future expansions in manufacturing capacity are expected, despite some COVID-19 related delays.
ImmuCell Corporation (Nasdaq: ICCC) announced its Q2 2020 financial results, reporting a 9% increase in product sales to $3 million compared to Q2 2019. For the six-month period, sales rose 11% to $7.9 million. Despite these gains, the company faced a net loss of $766,000, or $0.11 per share, compared to a loss of $627,000 in the same quarter last year. Gross margins declined to 43% from 46% year-over-year. However, cash reserves increased to $9.6 million, and the backlog of orders was reduced to approximately $945,000 as of June 30, 2020.